The issue of clarithromycin and increased cardiac deaths #4 - Where are the potential sources of variability?

1. Bioavailability
Regardless of its touted lipophilicity, clarithromycin has a reported average bioavailability of only about 50%. Generally, as a guiding principle, the lower the bioavailability, the greater the potential for variability in systemic availability.

2. Uncertain target site concentrations
There are two associated problems here.

Firstly, clarithromycin has an elimination half life of about 3-5 hours at low doses and 5-7 at higher doses. At a 12 hourly dosing intervals, there will be significant fluctuations in the plasma concentration profile. Even if it is administered at 8 hourly intervals, and if half-life is assumed to be at the high end of the range, say 8 hours, there will be at least a 2 fold fluctuation between peaks and trough. While this may meet the needs of anti-bacterial efficacy (assuming we keep trough levels above MIC), the levels of the peaks may predispose to cardiac toxicity if it is able to inhibit HERG potassium channels. To some extent, we can mitigate the fluctuations by using extended release formulations, but this may be at the expense of even more variability in bioavailability.

[source:http://medlibrary.org/lib/images-rx/clarithromycin-24/img-0238.jpg]

Comparison between normal formulation and extended release formulations

Secondly, since we do not routinely measure either plasma or tissue concentrations, we have little idea if adequate concentrations are being achieved at the target site. Here, there is some more uncertainty. Tissue and cellular concentrations tend to be higher than plasma unbound concentrations, but concentrations in the extra-cellular fluid (where the bugs are) are variable and may be lower than unbound concentrations of clarithromycin. These are functions of variable protein binding and the variable net activities of specific influx and efflux membrane transporters.

Consequent upon the previous two points, the differential effects of clarithromycin on the bacteria and on HERG channels may be variable between individuals not only because they relate to different effect compartments but the latter may relate to heights of the peak while the former to trough concentrations being above the MIC.

[Source:http://www.fda.gov/ohrms/dockets/ac/03/briefing/Image66.gif]

Relationship between QT prolongation ad clarithromycin concentrations

Although the IC50 for clarithromycin on the HERG channel is about a 100 times higher than the MIC, arrhythmic risk is associated with lower extent of inhibition. Hence cardiac risk is seen at much lower IC10 or IC20 concentrations

Added to all these, is the uncertainty contributed by an active 14-OH metabolite of clarithromycin.

3. Inter-individual variability in pharmacokinetics
Clarithromycin is both a substrate and inhibitor of CYP3A4. This metabolic pathway is also responsible to generating the active 14-OH metabolite. Variable CYP3A4 activity therefore results in a variable mix of clarithromycin and its active 14-OH metabolite.

There is a very high extent of variabilty in CYP3A4 activity in any population studied. There are also significant differences in activity between men and women (women generally higher). While there are genetic polymorphisms associated with CYP3A4, no single genetic variant has been able to account for the variability within a population. On the other hand, CYP3A4 is also vulnerable to many food and drug interactions.

To make matters more complicated, clarithromycin inhibits its own metabolism by CYP3A4, and exhibits a non-linear pharmacokinetic profile.

4. Inter-individual variability in susceptibility to QT prolongation
The HERG potassium channel gene is genetically polymorphic and variants may predispose to variable susceptibility to QT prolongation. Added to this is the uncertainty about appropriate dosing regiments between different ethnic populations, who may have different body weights and distributional volumes, as well as different exposures to CYP3A4 food and drug interactions.

5. Variability in microbial susceptibility
Apart from differences in anti-microbial efficacy due to variability in drug permeation to target sites, bacteria do differ in how susceptible they are to concentrations of clarithromycin. While sensitive bacteria generally have MICs in easily achievable range, resistance genes have become more prevalent and differences in bacterial sensitivity has become more common.

6. Compliance issues
One must never forget the variability that may be caused by failure of the patient to medicate according to instructions, leading to highly irregular dosing intervals and therefore variable degree of fluctuations in circulating drug concentrations.


Taking all these uncertainties into consideration, the question is how to ensure the patient gets optimal dosing? Think about it.

[To be continued]